- Home
- WIX vs VKTX Comparison
WIX vs VKTX Comparison
Compare WIX & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIX | VKTX |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WIX | VKTX |
|---|---|---|
| Price | $76.59 | $34.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 7 |
| Target Price | ★ $134.67 | $95.86 |
| AVG Volume (30 Days) | 1.6M | ★ 1.6M |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.80 | N/A |
| Revenue Next Year | $13.21 | N/A |
| P/E Ratio | $28.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $22.96 |
| 52 Week High | $190.92 | $43.15 |
Technical Indicators
Market Signals| Indicator | WIX | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.91 | 49.73 |
| Support Level | $75.00 | $29.56 |
| Resistance Level | $93.82 | $36.69 |
| Average True Range (ATR) | 4.70 | 1.42 |
| MACD | -0.37 | 0.04 |
| Stochastic Oscillator | 37.57 | 47.70 |
Price Performance
Historical ComparisonAbout WIX Wix.com Ltd.
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years, it has invested heavily and introduced its Wix Studio offering for partners, which are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.